Epitope editing of KIT enables antibody-based, non-genotoxic conditioning that selectively enriches therapeutic BCL11A-edited hematopoietic stem/progenitor cells, supporting durable engraftment and fetal hemoglobin induction for sickle cell disease and beta-thalassemia

Scientists developed a non-genotoxic method to edit stem cells for transplantation. This technique modifies cell surface proteins, allowing for selective enrichment of therapeutic cells. The method involves altering specific amino acids on the KIT protein, preventing antibodies from binding and depleting the cells. This allows for the use of antibody-based conditioning without harming the transplanted cells. This breakthrough offers a safer alternative to chemotherapy and radiation for stem cell therapies, potentially benefiting patients with sickle cell disease and beta-thalassemia.